サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434838

自己細胞治療市場：供給源、適応症、エンドユーザー別-2024-2030年の世界予測

Autologous Cell Therapies Market by Source (Bone Marrow, Chondrocytes, Epidermis), Indication (Autoimmune Disorders, Cancer, Cardiovascular Disorders), End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
自己細胞治療市場：供給源、適応症、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

自己細胞治療市場規模は2023年に81億1,000万米ドルと推計され、2024年には92億4,000万米ドルに達し、CAGR 14.52%で2030年には209億6,000万米ドルに達すると予測されます。

自己細胞治療の世界市場

主な市場の統計
基準年[2023］ 81億1,000万米ドル
予測年[2024］ 92億4,000万米ドル
予測年 [2030] 209億6,000万米ドル
CAGR（%） 14.52%
自己細胞治療 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは自己細胞治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、自己細胞治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-自己細胞治療市場の市場規模および予測は？

2-自己細胞治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-自己細胞治療市場における技術動向と規制の枠組みは？

4-自己細胞治療市場における主要ベンダーの市場シェアは？

5-自己細胞治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で慢性疾患の発生率が増加
      • 新たな用途に向けた医薬品開発への注力の拡大
      • ヘルスケアインフラの改善に伴い、個別化医療のニーズが高まる
    • 抑制要因
      • 自家細胞療法に伴う高額な費用
    • 機会
      • 自家細胞治療薬の製造の分散化に向けた技術の進歩
      • 細胞ベースの調査への政府投資の増加
    • 課題
      • 長い納期と限られた有効期限に伴う問題
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 自己細胞治療市場：ソース別

  • 骨髄
  • 軟骨細胞
  • 表皮
  • 造血幹細胞
  • 間葉系幹細胞

第7章 自己細胞治療市場適応症別

  • 自己免疫疾患
  • がん
  • 心血管疾患
  • 神経変性疾患
  • 整形外科
  • 創傷治癒

第8章 自己細胞治療市場：エンドユーザー別

  • 学術調査機関
  • 外来手術センター
  • 病院とクリニック

第9章 南北アメリカの自己細胞治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の自己細胞治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの自己細胞治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abata Therapeutics
    • Achilles Therapeutics plc
    • Adaptimmune Therapeutics PLC
    • Adicet Bio Inc.
    • AIVITA Biomedical, Inc.
    • Aspen Neuroscienc Inc.
    • Bellicum Phamaceuticals, Inc.
    • BioLineRx Ltd.
    • BioSpace, Inc.
    • BrainStorm Cell Limited.
    • Bristol-Myers Squibb Company
    • Carisma Therapeutics Inc.
    • Catalent, Inc.
    • Cell Therapy Catapult Ltd.
    • Fate Therapeutics Inc.
    • GentiBio, Inc.
    • IASO BioTherapeutics
    • Kyverna Therapeutics, Inc.
    • NOVADIP Biosciences S.A.
    • Orchard Therapeutics Inc.
    • T-knife Therapeutics, Inc.
    • ThermoGenesis Holdings, Inc.
    • Triumvira Immunologics Inc.
    • Vita Therapeutics, Inc.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AUTOLOGOUS CELL THERAPIES MARKET DYNAMICS
  • FIGURE 7. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 8. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CHONDROCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EPIDERMIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HAEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 150. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. AUTOLOGOUS CELL THERAPIES MARKET LICENSE & PRICING
目次
Product Code: MRR-69324464D2C7

[192 Pages Report] The Autologous Cell Therapies Market size was estimated at USD 8.11 billion in 2023 and expected to reach USD 9.24 billion in 2024, at a CAGR 14.52% to reach USD 20.96 billion by 2030.

Global Autologous Cell Therapies Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.11 billion
Estimated Year [2024] USD 9.24 billion
Forecast Year [2030] USD 20.96 billion
CAGR (%) 14.52%
Autologous Cell Therapies Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autologous Cell Therapies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autologous Cell Therapies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autologous Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Abata Therapeutics, Achilles Therapeutics plc, Adaptimmune Therapeutics PLC, Adicet Bio Inc., AIVITA Biomedical, Inc., Aspen Neuroscienc Inc., Bellicum Phamaceuticals, Inc., BioLineRx Ltd., BioSpace, Inc., BrainStorm Cell Limited., Bristol-Myers Squibb Company, Carisma Therapeutics Inc., Catalent, Inc., Cell Therapy Catapult Ltd., Fate Therapeutics Inc., GentiBio, Inc., IASO BioTherapeutics, Kyverna Therapeutics, Inc., NOVADIP Biosciences S.A., Orchard Therapeutics Inc., T-knife Therapeutics, Inc., ThermoGenesis Holdings, Inc., Triumvira Immunologics Inc., and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source
    • Bone Marrow
    • Chondrocytes
    • Epidermis
    • Haematopoietic Stem Cells
    • Mesenchymal Stem Cells
  • Indication
    • Autoimmune Disorders
    • Cancer
    • Cardiovascular Disorders
    • Neurodegenerative Disorders
    • Orthopedics
    • Wound Healing
  • End-User
    • Academics & Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Autologous Cell Therapies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autologous Cell Therapies Market?

3. What are the technology trends and regulatory frameworks in the Autologous Cell Therapies Market?

4. What is the market share of the leading vendors in the Autologous Cell Therapies Market?

5. Which modes and strategic moves are suitable for entering the Autologous Cell Therapies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Autologous Cell Therapies Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in incidences of chronic diseases worldwide
      • 5.1.1.2. Expanding focus on drug development for new applications
      • 5.1.1.3. Growing need for personalized medicines with improving healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with autologous cell therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for decentralizing manufacturing of autologous cell therapy
      • 5.1.3.2. Rising government investments in cell-based research
    • 5.1.4. Challenges
      • 5.1.4.1. Problems associated with long turnaround time and limited shelf life
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Autologous Cell Therapies Market, by Source

  • 6.1. Introduction
  • 6.2. Bone Marrow
  • 6.3. Chondrocytes
  • 6.4. Epidermis
  • 6.5. Haematopoietic Stem Cells
  • 6.6. Mesenchymal Stem Cells

7. Autologous Cell Therapies Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Disorders
  • 7.3. Cancer
  • 7.4. Cardiovascular Disorders
  • 7.5. Neurodegenerative Disorders
  • 7.6. Orthopedics
  • 7.7. Wound Healing

8. Autologous Cell Therapies Market, by End-User

  • 8.1. Introduction
  • 8.2. Academics & Research Institutes
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Autologous Cell Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autologous Cell Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Cell Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abata Therapeutics
    • 13.1.2. Achilles Therapeutics plc
    • 13.1.3. Adaptimmune Therapeutics PLC
    • 13.1.4. Adicet Bio Inc.
    • 13.1.5. AIVITA Biomedical, Inc.
    • 13.1.6. Aspen Neuroscienc Inc.
    • 13.1.7. Bellicum Phamaceuticals, Inc.
    • 13.1.8. BioLineRx Ltd.
    • 13.1.9. BioSpace, Inc.
    • 13.1.10. BrainStorm Cell Limited.
    • 13.1.11. Bristol-Myers Squibb Company
    • 13.1.12. Carisma Therapeutics Inc.
    • 13.1.13. Catalent, Inc.
    • 13.1.14. Cell Therapy Catapult Ltd.
    • 13.1.15. Fate Therapeutics Inc.
    • 13.1.16. GentiBio, Inc.
    • 13.1.17. IASO BioTherapeutics
    • 13.1.18. Kyverna Therapeutics, Inc.
    • 13.1.19. NOVADIP Biosciences S.A.
    • 13.1.20. Orchard Therapeutics Inc.
    • 13.1.21. T-knife Therapeutics, Inc.
    • 13.1.22. ThermoGenesis Holdings, Inc.
    • 13.1.23. Triumvira Immunologics Inc.
    • 13.1.24. Vita Therapeutics, Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing